[go: up one dir, main page]

GT199900214A - Combinacion de cerivastatina y fibratos. - Google Patents

Combinacion de cerivastatina y fibratos.

Info

Publication number
GT199900214A
GT199900214A GT199900214A GT199900214A GT199900214A GT 199900214 A GT199900214 A GT 199900214A GT 199900214 A GT199900214 A GT 199900214A GT 199900214 A GT199900214 A GT 199900214A GT 199900214 A GT199900214 A GT 199900214A
Authority
GT
Guatemala
Prior art keywords
fibrates
combination
cerivastatin
inhibitor
disease
Prior art date
Application number
GT199900214A
Other languages
English (en)
Inventor
Joachim Ippen
Ulrike Schopen
Reiner Ziegler
Fritz Schuckler
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT199900214A publication Critical patent/GT199900214A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A LA COMBINACION DEL INHIBIDOR DE LA 3HIDROXI3METILGLUTARILCOENZIMAA (INHIBIDOR DE LA HMGCOA), CERIVASTATINA, CON FIBRATOS Y A SU USO EN LA PROFILAXIS Y TRATAMIENTO DE TRANSTORNOS Y ENFERMEDADES DEL METABOLISMO DE LOS LIPIDOS ASI COMO DE ENFERMEDADES CAUSADAS POR ELLO.
GT199900214A 1998-12-18 1999-12-16 Combinacion de cerivastatina y fibratos. GT199900214A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19858789A DE19858789A1 (de) 1998-12-18 1998-12-18 Kombination von Cerivastatin und Fibraten

Publications (1)

Publication Number Publication Date
GT199900214A true GT199900214A (es) 2001-06-08

Family

ID=7891784

Family Applications (1)

Application Number Title Priority Date Filing Date
GT199900214A GT199900214A (es) 1998-12-18 1999-12-16 Combinacion de cerivastatina y fibratos.

Country Status (19)

Country Link
US (1) US6511985B1 (es)
EP (1) EP1140082A1 (es)
KR (1) KR20010093845A (es)
CN (1) CN1330544A (es)
AR (1) AR021643A1 (es)
AU (1) AU3035600A (es)
BR (1) BR9916270A (es)
CA (1) CA2355295A1 (es)
CO (1) CO5160272A1 (es)
DE (1) DE19858789A1 (es)
GT (1) GT199900214A (es)
HN (1) HN1999000208A (es)
IL (1) IL143221A0 (es)
PE (1) PE20001325A1 (es)
PL (1) PL349389A1 (es)
SV (1) SV1999000250A (es)
TR (1) TR200101722T2 (es)
WO (1) WO2000037078A1 (es)
ZA (1) ZA200103918B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60129573T2 (de) 2000-09-20 2008-04-17 Jagotec Ag Verfahren zur sprühtrocknung von zusammensetzungen enthaltend fenofibrat
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
IL156445A0 (en) 2001-01-26 2004-01-04 Schering Corp Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
ME00145B (me) 2001-01-26 2010-10-10 Merck Sharp & Dohme Upotreba supstituisanih jedinjenja azetidinona za lečenje sitosterolemije
AU2001259099B2 (en) 2001-02-22 2005-12-22 Skyepharma Canada Inc. Fibrate-statin combinations with reduced fed-fasted effects
US20050032878A1 (en) 2001-08-07 2005-02-10 Arthur Deboeck Oral pharmaceutical composition containing a combination pparalpha and a hmg-coa reductase inhibitor
WO2003013607A1 (en) * 2001-08-07 2003-02-20 Galephar M/F ORAL PHARMACEUTICAL COMPOSITION CONTAINING A COMBINATION OF FENOFIBRATE AND A HMG-CoA REDUCTASE INHIBITOR
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
ES2272776T3 (es) 2001-09-21 2007-05-01 Schering Corporation Tratamiento de xantomas con derivados de azetidinona como inhibidores de la absorcion de esterol.
DE10200138A1 (de) * 2002-01-04 2003-07-17 Karl Winkler Kombination von einem PPAR-Agonisten mit PPAR-alpha Aktivität mit einem Induktor des LDL-Rezeptors
WO2004043457A1 (en) 2002-11-06 2004-05-27 Schering Corporation Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
US7411045B2 (en) * 2002-11-19 2008-08-12 A&G Pharmaceutical, Inc. Autocrine growth factor receptor antibodies and methods
US7192944B2 (en) 2003-03-07 2007-03-20 Schering Corp. Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
DE602004018617D1 (de) 2003-03-07 2009-02-05 Schering Corp Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
DE602004016123D1 (de) 2003-03-07 2008-10-09 Schering Corp Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
OA13174A (en) * 2003-05-30 2006-12-13 Ranbaxy Lab Ltd Substituted pyrrole derivatives and their use as HMG-Co inhibitors.
DE602004020649D1 (de) * 2003-11-07 2009-05-28 Jj Pharma Inc Hdl-verstärkende kombinationstherapie-komplexe
RU2007133601A (ru) * 2005-02-10 2009-03-20 Лайфсайкл Фарма А/С (Dk) УСТОЙЧИВАЯ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ФИКСИРОВАННУЮ ДОЗУ КОМБИНАЦИИ ФЕНОФИБРАТА И ИНГИБИТОРА HMG-CoA-РЕДУКТАЗЫ
WO2007054896A1 (en) * 2005-11-08 2007-05-18 Ranbaxy Laboratories Limited Process for (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
WO2008020314A2 (en) * 2006-03-14 2008-02-21 Ranbaxy Laboratories Limited Statin stabilizing dosage formulations
US20070269503A1 (en) * 2006-05-16 2007-11-22 James Walter Burgess Combinations of HMG CoA reductase inhibitors and negatively charged phospholipids and uses thereof
WO2008010087A2 (en) * 2006-07-14 2008-01-24 Ranbaxy Laboratories Limited Polymorphic forms of an hmg-coa reductase inhibitor and uses thereof
CN101534825A (zh) 2006-08-04 2009-09-16 Aska制药株式会社 含有贝特类药物的制剂及其制备方法
TWI407955B (zh) 2007-03-29 2013-09-11 Kowa Co 高脂血症之預防及／或治療劑
WO2023146320A1 (ko) * 2022-01-28 2023-08-03 동광제약 주식회사 로수바스타틴 또는 이의 약학적으로 허용되는 염 및 페노피브레이트를 함유하는 캡슐 제제

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2494112B1 (es) 1980-11-19 1986-01-10 Laruelle Claude
WO1988005296A2 (en) 1987-01-27 1988-07-28 Warner-Lambert Company Lpid regulating compositions
FR2627696B1 (fr) 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
CA2039763A1 (en) * 1990-04-30 1991-10-31 Henry Y. Pan Combination of pravastatin and a fibric acid derivative, and method for treating dyslipidemia using such combination
US5177080A (en) * 1990-12-14 1993-01-05 Bayer Aktiengesellschaft Substituted pyridyl-dihydroxy-heptenoic acid and its salts
FR2737121B1 (fr) 1995-07-27 1997-10-03 Cl Pharma Nouvelles formulations galeniques du fenofibrate et leurs applications
PT1017390E (pt) * 1997-07-31 2007-07-24 Kos Life Sciences Inc Comprimido revestido que compreende ácido nicotínico ou um composto metabolizado a ácido nicotínico sob uma forma de libertação prolongada, e um revestimento que contém um inibidor da hmg-coa-redutase sob uma forma de libertação imediata.

Also Published As

Publication number Publication date
CN1330544A (zh) 2002-01-09
PE20001325A1 (es) 2000-12-30
IL143221A0 (en) 2002-04-21
BR9916270A (pt) 2001-09-04
TR200101722T2 (tr) 2001-11-21
US6511985B1 (en) 2003-01-28
AU3035600A (en) 2000-07-12
HN1999000208A (es) 2000-11-22
SV1999000250A (es) 2000-10-16
DE19858789A1 (de) 2000-06-21
CO5160272A1 (es) 2002-05-30
WO2000037078A1 (de) 2000-06-29
ZA200103918B (en) 2002-05-15
KR20010093845A (ko) 2001-10-29
AR021643A1 (es) 2002-07-31
CA2355295A1 (en) 2000-06-29
PL349389A1 (en) 2002-07-15
EP1140082A1 (de) 2001-10-10

Similar Documents

Publication Publication Date Title
GT199900214A (es) Combinacion de cerivastatina y fibratos.
HN1998000132A (es) Combinaciones terapeuticas
ES2192301T3 (es) Derivados de resorcinol.
HN2001000217A (es) Nuevos tiadiazoles y oxadiazoles y su uso como inhibidores de fosfodiesterasa - 7
HN1999000066A (es) Formulaciones farmaceuticas
HN1998000124A (es) Terapia de combinacion
HN1998000139A (es) Pirimidin-4-ona y pirimidin-4-tiona novedosas como funguicidas
MXPA03000263A (es) Correlacion del objetivo de fuentes multiples.
HN2001000281A (es) Nuevas imidazotriazinonas sustituidas
GT199900215A (es) Formulaciones agroquimicas.
BR0113798A (pt) Derivados de resorcinol
HN1998000002A (es) Compuestos de quinolina y de quinazolina utiles en terapia
GT200300294A (es) Compuestos de indazol y composiciones farmaceuticas para inhibir proteinquinasas y procedimientos para su uso
TR200200260T2 (tr) N-desmetilzopiklonlarının üretim ve kullanım yöntemleri
HN1997000098A (es) Ccompuesto de indol 2, 3 sustituido como agentes antiinflamatorios y analgesicos.
ES2189992T3 (es) Reduccion del crecimiento del pelo.
BR0114903A (pt) 7-azaindóis, sua aplicação como inibidores da fosfodiesterase 4 e processos para a sua preparação
NO20031860L (no) Kahalalid F
ES2170798T3 (es) Benzopiranos y su uso como agentes terapeuticos.
BR0115139A (pt) Compostos bis-heterocìclicos com atividade antitumor e quimiossensibilizante
CU23269A3 (es) Bromhidrato de eletriptan monohidratado
BR0012553A (pt) Pastilhas contendo ambroxol
PA8453601A1 (es) Inhibidores de la farnesil transferasa combinados con inhibidores de la hmg coa reductasa para tratamiento del cancer
ES2174297T3 (es) Nuevos derivados de piranosidos.
NO20005548L (no) Mykobakterieinhibitorer